Lexeo Therapeutics (LXEO) Competitors $3.42 -0.11 (-3.20%) As of 09:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LXEO vs. CKPT, SNDL, TRDA, OLMA, ARCT, HRTX, SEPN, BNTC, FULC, and ATYRShould you be buying Lexeo Therapeutics stock or one of its competitors? The main competitors of Lexeo Therapeutics include Checkpoint Therapeutics (CKPT), SNDL (SNDL), Entrada Therapeutics (TRDA), Olema Pharmaceuticals (OLMA), Arcturus Therapeutics (ARCT), Heron Therapeutics (HRTX), Septerna (SEPN), Benitec Biopharma (BNTC), Fulcrum Therapeutics (FULC), and Atyr PHARMA (ATYR). These companies are all part of the "pharmaceutical products" industry. Lexeo Therapeutics vs. Checkpoint Therapeutics SNDL Entrada Therapeutics Olema Pharmaceuticals Arcturus Therapeutics Heron Therapeutics Septerna Benitec Biopharma Fulcrum Therapeutics Atyr PHARMA Lexeo Therapeutics (NASDAQ:LXEO) and Checkpoint Therapeutics (NASDAQ:CKPT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, community ranking, institutional ownership, earnings and analyst recommendations. Which has more volatility and risk, LXEO or CKPT? Lexeo Therapeutics has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Checkpoint Therapeutics has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Do analysts recommend LXEO or CKPT? Lexeo Therapeutics presently has a consensus price target of $20.20, indicating a potential upside of 491.16%. Checkpoint Therapeutics has a consensus price target of $4.33, indicating a potential upside of 4.04%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Lexeo Therapeutics is more favorable than Checkpoint Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexeo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Checkpoint Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the MarketBeat Community prefer LXEO or CKPT? Checkpoint Therapeutics received 154 more outperform votes than Lexeo Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Lexeo Therapeutics an outperform vote while only 67.16% of users gave Checkpoint Therapeutics an outperform vote. CompanyUnderperformOutperformLexeo TherapeuticsOutperform Votes28100.00% Underperform VotesNo VotesCheckpoint TherapeuticsOutperform Votes18267.16% Underperform Votes8932.84% Which has better valuation & earnings, LXEO or CKPT? Checkpoint Therapeutics has lower revenue, but higher earnings than Lexeo Therapeutics. Checkpoint Therapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexeo Therapeutics$650K174.51-$66.39M-$3.30-1.04Checkpoint Therapeutics$41K8,509.20-$51.85M-$1.29-3.23 Does the media refer more to LXEO or CKPT? In the previous week, Lexeo Therapeutics had 21 more articles in the media than Checkpoint Therapeutics. MarketBeat recorded 22 mentions for Lexeo Therapeutics and 1 mentions for Checkpoint Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.46 beat Checkpoint Therapeutics' score of -0.33 indicating that Lexeo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Checkpoint Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is LXEO or CKPT more profitable? Checkpoint Therapeutics' return on equity of 0.00% beat Lexeo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lexeo TherapeuticsN/A -57.66% -48.18% Checkpoint Therapeutics N/A N/A -659.07% Do institutionals & insiders have more ownership in LXEO or CKPT? 60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 22.0% of Checkpoint Therapeutics shares are owned by institutional investors. 4.5% of Lexeo Therapeutics shares are owned by insiders. Comparatively, 2.1% of Checkpoint Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryLexeo Therapeutics beats Checkpoint Therapeutics on 13 of the 18 factors compared between the two stocks. Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LXEO vs. The Competition Export to ExcelMetricLexeo TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$112.37M$2.97B$5.42B$8.48BDividend YieldN/A1.72%5.22%4.11%P/E Ratio-1.0731.5826.7820.05Price / Sales174.51414.63395.49116.44Price / CashN/A168.6838.2534.62Price / Book0.803.376.874.61Net Income-$66.39M-$72.17M$3.22B$248.19M7 Day Performance27.03%7.60%5.69%2.56%1 Month Performance6.45%11.15%12.66%16.18%1 Year Performance-77.22%-26.57%18.01%8.16% Lexeo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LXEOLexeo Therapeutics2.8961 of 5 stars$3.42-3.2%$20.20+491.2%-74.4%$112.37M$650,000.00-1.0758News CoverageAnalyst RevisionCKPTCheckpoint Therapeutics1.9501 of 5 stars$4.16-0.2%$4.33+4.2%+104.9%$348.46M$41,000.00-2.2610News CoverageSNDLSNDL3.1518 of 5 stars$1.32+2.3%$3.63+174.6%-44.6%$346.86M$927.61M-4.26580News CoveragePositive NewsTRDAEntrada Therapeutics2.9644 of 5 stars$8.82+5.3%$25.67+191.0%-46.2%$334.75M$172.22M5.55110News CoverageAnalyst ForecastAnalyst RevisionOLMAOlema Pharmaceuticals2.3086 of 5 stars$4.76+3.5%$27.67+481.2%-46.6%$325.40MN/A-2.1770Positive NewsGap UpARCTArcturus Therapeutics2.9697 of 5 stars$11.59+5.6%$59.20+410.8%-58.4%$314.33M$138.39M-5.22180Gap UpHRTXHeron Therapeutics3.9238 of 5 stars$2.05-2.8%$5.50+168.3%-43.5%$312.76M$148.52M-11.39300Positive NewsSEPNSepterna2.0964 of 5 stars$6.98+4.3%$33.00+372.8%N/A$310.72M$1.08M0.00N/AEarnings ReportAnalyst RevisionBNTCBenitec Biopharma2.4448 of 5 stars$13.14-3.6%$24.71+88.1%+33.0%$308.15M$80,000.00-8.7020News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionFULCFulcrum Therapeutics0.7716 of 5 stars$5.68+5.8%$8.63+51.8%-15.5%$306.60M$80M-18.32100ATYRAtyr PHARMA2.8502 of 5 stars$3.24-1.2%$18.60+474.1%N/A$288.37M$235,000.00-3.4553News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies Checkpoint Therapeutics Competitors SNDL Competitors Entrada Therapeutics Competitors Olema Pharmaceuticals Competitors Arcturus Therapeutics Competitors Heron Therapeutics Competitors Septerna Competitors Benitec Biopharma Competitors Fulcrum Therapeutics Competitors Atyr PHARMA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LXEO) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
